Breaking News

Gallus Enters ADC Mfg. Agreement with Progenics

August 21, 2014

To produce prostate cancer drug at its commercial facility in St. Louis

Gallus BioPharmaceuticals, LLC has been selected by Progenics Pharmaceuticals, Inc. to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in its PSMA ADC product candidate. Gallus will produce the antibody at its commercial manufacturing facility in St. Louis, MO.
 
PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug to prostate cancer cells by targeting PSMA, a protein that is a biomarker of prostate cancer. The PSMA antibody is designed enter the cancer cell and release active anti-cancer drug.
 
“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody," said Mark R. Bamforth, president and chief executive officer of Gallus. "We look forward to working with Progenics as they advance this treatment for patients with prostate cancer."
 
"Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, Ph.D., senior vice president of manufacturing at Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks